AMSTERDAM, THE NETHERLANDS--(MARKET WIRE)--Jul 14, 2006 -- After acquiring the CE registration of MammaPrint® in 2005, Agendia’s second micro array service, CupPrint®*, has also acquired Medical Device registration at the Dutch Healthcare Inspectorate. “With the CE registration of both its products and the ISO 17025 accreditation of its Laboratory services, Agendia is in a unique position to market its products and to provide a legal basis for its use in clinical practice,” says Laura van ‘t Veer, COO of Agendia.
About CupPrint®*
This test is intended for patients with a Cancer of Unknown Primary, which represents around 4% of all cancers. For these patients, assessing the origin of the primary tumor, which guides treatment, is challenging by conventional techniques and often a lengthy process. CupPrint can assist in identifying the primary tumor site, which can support the doctor in deciding on the optimal treatment of the patient. CupPrint® is available in Europe through the sales network of Agendia.
About Agendia
Agendia is a world leader in gene expression analysis-based diagnostics. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first to commercialize a prognostic test -- MammaPrint® -- that predicts the chance of breast cancer recurrence. CupPrint®*, the second product in the market of Agendia, is used for the identification of Cancers of Unknown Primary. Agendia maintains close ties with NKI/AVL, ensuring access to the latest developments in cancer research. Apart from the development of new cancer diagnostics, Agendia offers its expertise in finding new predictive gene expression profiles to companies focusing on new drug development in the area of oncology.
*CupPrint is based on a license to the TUO database of AviaraDx.
More information about Agendia BV is available at www.agendia.com
Contact: CONTACT INFORMATION: Agendia: Bernhard Sixt CEO of Agendia +31-20-5129161 Email Contact
Source: Agendia BV
